

ABLE

MIC AND PK/PD FOR TARGETING
ANTIMICROBIAL THERAPY OF CRITICAL
INFECTIONS IN HIGH RISK PATIENTS

AB BIODISK LABORATORY for EDUCATION – March 5-7, 2008, Stockholm, Solna, Sweden

Escalating antimicrobial resistance against a backdrop of increasing critical care populations questions the validity of using oversimplified S-I-R susceptibility testing concepts. The importance of “real” MIC testing, use of conservative breakpoints and ability to detect the non-susceptible phenotypes are today’s priorities. The use of pharmacodynamic indices to target the therapy of compromised patients can impact treatment outcome, resistance development and cost-savings. This ABLE session will address some of these issues and explore how interactions between clinicians, clinical pharmacists and clinical microbiologists can provide further data and improvements to optimise treatment outcomes. The predefined gradient technology, various applications and its advantage for resistance detection will also be presented in theory and practice.

DAY ONE – MARCH 5

Introductions and coffee		08:30 - 09:00
1. Pharmacodynamic principles to target antibiotic choice, dose and dosage regimens to optimise treatment outcome	Tom Lodise	09:00 - 09:40
2. Clinical needs for MIC testing from a critical care perspective	TBC	09:50 - 10:30
Coffee		10:30 - 10:45
3. Etest, a theranostic tool for organism, resistance and clinical needs	Anne Yusof	10:45 - 11:25
4. The microbiology laboratory – clinicians, please ask for more MICs!	Audrey Wanger	11:35 - 12:15
Lunch		12:20 - 13:20
5. Overview of laboratory sessions: set up and reading of Etest	Maria Tollin	13:00 - 14:00
6. GROUP A: Set up of different applications GROUP B: Demonstration stations	Laboratory team	14:15 - 15:30
Coffee		15:30 - 15:45
7. GROUP B: Set up of different applications GROUP A: Demonstration stations	Laboratory team	15:45 - 17:00
Reception		17:00 - 17:45
Bus to dinner		18:00 - 20:00

DAY TWO – MARCH 6

8. Direct Etest method for respiratory samples to improve antibiotic use in Ventilator Associated Pneumonia (VAP)	TBC	08:30 - 09:10
9. Etest for direct testing of ICU specimens – the Sheffield, UK Project	Robert Townsend	09:20 - 09:50
Coffee		09:50 - 10:05
10. GISA, hGISA – time to take daily action in the clinical laboratory?	Tim Walsh	10:05 - 10:45
11. Vancomycin and MRSA - PK/PD challenges and opportunities?	Tom Lodise	10:55 - 11:35
Lunch		11:40 - 12:40
12. Predefined gradients for antimicrobial combination testing	Anne Yusof	12:40 - 13:10
13. Reading 24-hour results and demonstration stations	Laboratory team	13:10 - 15:10
Coffee		15:10 - 15:25
14. Antifungal susceptibility testing to improve treatment and saves costs	Audrey Wanger	15:30 - 16:10

15. MIC testing solving clinical needs and the breakpoint dilemma? TBC 16:20 - 16:40

DAY THREE – MARCH 7

16. Cystic fibrosis- newer perspectives in antimicrobial susceptibility testing Tim Walsh 08:30 - 09:10

17. The Gram negative non-fermenter threat – patients at risk? Tim Walsh 09:20 - 10:00

Coffee

18. Reading 48-hour results Laboratory team 10:00 - 10:15
10:15 - 11:15

19. Discussion of results Maria Tollin 11:15 - 11:45

20. The MIC – ICU bench, a clinical must today? TBC 11:45 - 12:00

Lunch

21. Discussion and farewell 12:00 - 13:00
13:00 - 14:00

22. Demonstration stations (Optional)

FACULTY AND PRESENTERS

Thomas Lodise, PharmD, Albany College of Pharmacy, Albany, NY, USA

Timothy R. Walsh, PhD, Cardiff University, Cardiff, UK

Robert Townsend, MD, Sheffield Teaching Hospital, Sheffield, UK

Audrey Wanger, PhD, University of Texas, Houston, TX, USA

Anne Yusof, PharmD, AB BIODISK, Solna, Sweden

Maria Tollin, PhD, AB BIODISK, Solna, Sweden

Others to be confirmed

AB BIODISK
Dalvägen 10
169 56 Solna, Sweden
Tel. +46-(0)8-730 07 60
Fax. +46-(0)8-83 81 58
etest@abbiodisk.se
www.abbiodisk.com



ABLE MIC AND PK/PD FOR TARGETING THERAPY OF SERIOUS FUNGAL AND BACTERIAL INFECTIONS

AB BIODISK LABORATORY for EDUCATION – March 5-7, 2008, Stockholm, Solna, Sweden

Escalating antimicrobial resistance against a backdrop of increasing critical care populations questions the validity of using oversimplified S-I-R susceptibility testing concepts. The importance of “real” MIC testing, use of conservative breakpoints and ability to detect the non-susceptible phenotypes are today’s priorities. The use of pharmacodynamic indices to target the therapy of compromised patients can impact treatment outcome, resistance development and cost-savings. This ABLE session will address some of these issues and explore how interactions between clinicians, clinical pharmacists and clinical microbiologists can provide further data and improvements to optimise treatment outcomes. The predefined gradient technology, various applications and its advantage for resistance detection will also be presented in theory and practice.

REGISTRATION

Name: _____

Position: _____

Professional Background: MD (please specify) ICU Clinician ID Specialist ID Consult
 Other speciality

PhD / MSc Microbiology PharmD

Other academic degree _____ (Please specify)

Institution: _____

Department: _____

Address: _____

City/State: _____ Zip Code: _____

Country: _____ Email: _____

Telephone: _____ Fax: _____

PLEASE EMAIL YOUR REGISTRATION TO PETRA.PETERS@ABBIODISK.SE OR FAX +46-8-83 81 58.

PLEASE SEND A COPY TO YOUR LOCAL ETEST DISTRIBUTOR.

Updated course information is available at www.abbiodisk.com.

Courses are conducted at the ABLE facility, AB BIODISK, Stockholm, Solna, Sweden.

DISCLAIMER

Should the minimum number of participants not be met for an ABLE course, AB BIODISK reserves the right to postpone the course. All courses will be considered tentative until confirmed by AB BIODISK.

COST

Travel/hotel costs are to be covered by the participant and/or distributor. AB BIODISK covers the teaching sessions and food for three days.

Etest® and the Etest gradient strip are registered trademarks of AB BIODISK.

AB BIODISK
Dalvägen 10
169 56 Solna, Sweden
Tel. +46-(0)8-730 07 60
Fax. +46-(0)8-83 81 58
etest@abbiodisk.se
www.abbiodisk.com

